Knockdown of microRNA-214-3p Promotes Tumor Growth and Epithelial-Mesenchymal Transition in Prostate Cancer.

CRISPR/Cas9 EMT RNA sequencing microRNA prostate cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
23 Nov 2021
Historique:
received: 21 10 2021
revised: 17 11 2021
accepted: 19 11 2021
entrez: 10 12 2021
pubmed: 11 12 2021
medline: 11 12 2021
Statut: epublish

Résumé

Abnormal expression of microRNA miR-214-3p (miR-214) is associated with multiple cancers. In this study, we assessed the effects of CRISPR/Cas9 mediated miR-214 depletion in prostate cancer (PCa) cells and the underlying mechanisms. Knockdown of miR-214 promoted PCa cell proliferation, invasion, migration, epithelial-mesenchymal transition (EMT), and increased resistance to anoikis, a key feature of PCa cells that undergo metastasis. The reintroduction of miR-214 in miR-214 knockdown cells reversed these effects and significantly suppressed cell proliferation, migration, and invasion. These in vitro studies are consistent with the role of miR-214 as a tumor suppressor. Moreover, miR-214 knockout increased tumor growth in PCa xenografts in nude mice supporting its anti-oncogenic role in PCa. Knockdown of miR-214 increased the expression of its target protein, Protein Tyrosine Kinase 6 (PTK6), a kinase shown to promote oncogenic signaling and tumorigenesis in PCa. In addition, miR-214 modulated EMT as exhibited by differential regulation of E-Cadherin, N-Cadherin, and Vimentin both in vitro and in vivo. RNA-seq analysis of miR-214 knockdown cells revealed altered gene expression related to PCa tumor growth pathways, including EMT and metastasis. Collectively, our findings reveal that miR-214 is a key regulator of PCa oncogenesis and is a potential novel therapeutic target for the treatment of the disease.

Identifiants

pubmed: 34884984
pii: cancers13235875
doi: 10.3390/cancers13235875
pmc: PMC8656576
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : U01CA194730
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01 MD012767
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01MD012767
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54MD012392
Pays : United States
Organisme : NIMHD NIH HHS
ID : U24 MD015970
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD012392
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA194730
Pays : United States

Références

Onco Targets Ther. 2020 Jan 28;13:803-811
pubmed: 32095078
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
PLoS One. 2013 Oct 22;8(10):e76994
pubmed: 24167554
Oncotarget. 2017 May 23;8(21):35376-35389
pubmed: 28430640
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498
pubmed: 23830918
Gene. 2020 Jan 15;724:144146
pubmed: 31634561
Int J Oncol. 2019 Dec;55(6):1194-1212
pubmed: 31638194
Crit Rev Oncog. 2016;21(3-4):155-168
pubmed: 27915969
Tumour Biol. 2016 Jun;37(6):8239-48
pubmed: 26718213
Oncogene. 2013 Sep 5;32(36):4304-12
pubmed: 23027128
Gene. 2016 May 25;583(1):48-57
pubmed: 26945629
Clin Cancer Res. 2018 Jun 15;24(12):2732-2739
pubmed: 29559559
Int J Mol Med. 2018 Dec;42(6):3027-3036
pubmed: 30272290
Lab Invest. 2004 Dec;84(12):1666-76
pubmed: 15467730
Hepatology. 2014 Aug;60(2):598-609
pubmed: 24616020
Cancer Sci. 2020 Aug;111(8):2883-2894
pubmed: 32535957
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):E4762-9
pubmed: 24248375
Curr Opin Pharmacol. 2010 Dec;10(6):662-9
pubmed: 20832360
Int J Mol Sci. 2018 Mar 19;19(3):
pubmed: 29562686
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):3710-3716
pubmed: 32329847
World J Mens Health. 2014 Dec;32(3):167-75
pubmed: 25606566
Mol Cancer. 2015 Aug 07;14:149
pubmed: 26245467
Mol Aspects Med. 2010 Apr;31(2):205-14
pubmed: 20153362
Sci Rep. 2019 Jul 5;9(1):9776
pubmed: 31278310
Cancer Res. 2016 Aug 1;76(15):4406-17
pubmed: 27302163
Int J Mol Sci. 2020 Jun 23;21(12):
pubmed: 32585812
PLoS One. 2012;7(9):e44206
pubmed: 22962603
Cell Mol Biol Lett. 2019 Mar 14;24:22
pubmed: 30915129
Oncotarget. 2017 Sep 21;8(50):87675-87683
pubmed: 29152111
PLoS One. 2012;7(12):e52106
pubmed: 23300597
Int J Cancer. 2006 Nov 1;119(9):2026-9
pubmed: 16671092
Chin J Cancer. 2014 Mar;33(3):140-7
pubmed: 24016392
Br J Cancer. 2016 Sep 6;115(6):741-51
pubmed: 27537384
Cell. 2012 Mar 16;148(6):1172-87
pubmed: 22424228
J Pathol. 2021 Apr;253(4):384-395
pubmed: 33314197
Oncogene. 2016 Sep 8;35(36):4752-61
pubmed: 26898757
Future Oncol. 2015;11(2):349-63
pubmed: 25591843
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24184-24195
pubmed: 31704767
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Tumour Biol. 2016 Nov;37(11):14605-14614
pubmed: 27619677
Oncogene. 2016 Apr 21;35(16):2087-97
pubmed: 26234674
Int J Biochem Cell Biol. 2011 Apr;43(4):632-41
pubmed: 21216304
Biochim Biophys Acta Mol Basis Dis. 2019 Oct 1;1865(10):2685-2693
pubmed: 31351129
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Am J Transl Res. 2016 Apr 15;8(4):1719-29
pubmed: 27186295
Cancer Res. 2013 Sep 1;73(17):5426-37
pubmed: 23856248
J Med Chem. 2019 Dec 26;62(24):10927-10954
pubmed: 31419130
Cold Spring Harb Mol Case Stud. 2017 Jan;3(1):a001115
pubmed: 28050598
Nat Rev Cancer. 2013 Oct;13(10):685-700
pubmed: 24060861
Sci Rep. 2014 Feb 03;4:3943
pubmed: 24487629
Mol Cancer. 2015 Dec 15;14:208
pubmed: 26666173
Avicenna J Med Biotechnol. 2010 Oct;2(4):161-79
pubmed: 23407304
Cancer Cell. 2017 Sep 11;32(3):282-293
pubmed: 28898694
Am J Cancer Res. 2016 Jan 15;6(2):127-40
pubmed: 27186391
Oncotarget. 2017 Mar 28;8(13):20881-20894
pubmed: 28152509
Tumour Biol. 2016 Jun;37(6):7473-80
pubmed: 26678890
Cancer Manag Res. 2020 Jul 28;12:6477-6491
pubmed: 32801887
Cancer Lett. 2016 Feb 28;371(2):301-13
pubmed: 26683775
Cancer Biomark. 2019;26(2):193-202
pubmed: 31403941
Am J Clin Exp Urol. 2020 Feb 25;8(1):1-8
pubmed: 32211448
J Transl Med. 2012 Nov 20;10:228
pubmed: 23164426
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Biochem Biophys Res Commun. 2017 Mar 11;484(3):623-630
pubmed: 28137590
J Invest Dermatol. 2015 Apr;135(4):960-969
pubmed: 25501033
PLoS One. 2014 May 01;9(5):e96060
pubmed: 24788754
J Exp Clin Cancer Res. 2018 Jul 18;37(1):160
pubmed: 30021600

Auteurs

Patrice Cagle (P)

Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.

Nikia Smith (N)

Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.

Timothy O Adekoya (TO)

Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.

Yahui Li (Y)

Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.

Susy Kim (S)

Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.

Leslimar Rios-Colon (L)

Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.

Gagan Deep (G)

Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
Wake Forest Baptist Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.

Suryakant Niture (S)

Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.

Christopher Albanese (C)

Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA.

Simeng Suy (S)

Department of Radiation Medicine, Georgetown University Hospital, Washington, DC 20007, USA.

Sean P Collins (SP)

Department of Radiation Medicine, Georgetown University Hospital, Washington, DC 20007, USA.

Deepak Kumar (D)

Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC 27707, USA.
Department of Pharmaceutical Sciences, North Carolina Central University, Durham, NC 27707, USA.

Classifications MeSH